Pamela Holland - Alpine Immune VP Research
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
Insider
Pamela Holland is VP Research of Alpine Immune Sciences
| Phone | 206 788 4545 |
| Web | https://www.alpineimmunesciences.com |
Alpine Immune Management Efficiency
The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.Alpine Immune Sciences currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Alpine Immune Sciences has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpine Immune's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
| Deepak MD | Tenaya Therapeutics | 58 | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| FACP MD | IGM Biosciences | 63 | |
| Oliver Daltrop | MoonLake Immunotherapeutics | N/A | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Nicholas Keen | Bicycle Therapeutics | 56 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Lisa Decker | IGM Biosciences | 55 | |
| Matthias Bodenstedt | MoonLake Immunotherapeutics | 36 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 |
Alpine Immune Sciences Leadership Team
Elected by the shareholders, the Alpine Immune's board of directors comprises two types of representatives: Alpine Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpine. The board's role is to monitor Alpine Immune's management team and ensure that shareholders' interests are well served. Alpine Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpine Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Temre Johnson, Head Communications | ||
| Remy Durand, Chief Officer | ||
| Andrew MD, Chief Officer | ||
| Paul Rickey, CFO, Senior Vice President Secretary | ||
| Stanford MD, President Development | ||
| Wayne Gombotz, Chief Officer | ||
| Mitchell MD, Executive CEO | ||
| Pamela Holland, VP Research | ||
| Wolfgang MD, Chief Officer | ||
| Christina Yi, Chief Officer |
Alpine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpine Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Shares Owned By Insiders | 4.60 % | |||
| Shares Owned By Institutions | 99.46 % | |||
| Number Of Shares Shorted | 3.89 M | |||
| Price To Earning | (32.69) X |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |